Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical, Inc. (LFCR)
:LFCR
LFCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.68 - $8.85
Previous CloseN/A
Volume140.23K
Average Volume (3M)132.82K
Market Cap
$277.57M
Enterprise Value$418.81M
Total Cash (Recent Filing)$5.42M
Total Debt (Recent Filing)$130.34M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Oct 03, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding37,407,920
10 Day Avg. Volume144,361
30 Day Avg. Volume132,825
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue3.21
Enterprise Value/Gross Profit9.61
Enterprise Value/Ebitda-38.12
Forecast
1Y Price Target
$8.75Price Target Upside17.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Business DevelopmentLifecore appears to be making notable headway on successfully serving existing customers and winning new projects to bolster its pipeline and support its next leg of growth.
Financial PerformanceLifecore Biomedical, Inc. delivered a solid fourth quarter result which included a slightly better than expected performance in terms of revenue, adjusted EPS, and adjusted EBITDA.
Strategic PartnershipsLifecore is a key beneficiary of Alcon’s ongoing strategic shift away from another third-party manufacturer as well as regional product expansion in the Asia-Pacific market.
Bears Say
CDMO Revenue DeclineThe company’s top line decline in CDMO was primarily impacted by $4.4 million of lower development revenue due to the completion of a customer project as well as the timing of customer project lifecycles.
Debt And ValuationMaintaining LFCR shares at a MARKET PERFORM due to Lifecore’s significant leverage (over 8x) and valuation.
Regulatory RisksLifecore could face quality-assurance problems with the FDA or another regulator; the company has a high debt burden in comparison to its peers.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was $3.68 and its highest was $8.85 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is $277.57M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Oct 03, 2025 which is in 48 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Lifecore Biomedical, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.035.
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Undervalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,407,920 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Lifecore Biomedical, Inc. reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -6.701%.
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in LFCR
Lifecore Biomedical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.75 (17.92% Upside)
$8.75 (17.92% Upside)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.71%
12-Months-Change
Fundamentals
Return on Equity
-76.41%
Trailing 12-Months
Asset Growth
-12.55%
Trailing 12-Months
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical (LFCR) is a prominent company operating in the biotechnology and pharmaceutical sectors, specializing in the development, manufacturing, and commercialization of high-purity, injectable-grade hyaluronic acid products. The company provides contract development and manufacturing services for medical device and pharmaceutical companies, focusing on products that meet stringent regulatory standards.
LFCR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic advancements, new partnerships, and operational improvements, but was weighed down by decreased quarterly revenue and a significant net loss. The company remains optimistic about future growth and financial recovery.View all LFCR earnings summariesLFCR Stock 12 Month Forecast
Average Price Target
$8.75
▲(17.92% Upside)
Technical Analysis
Emergent Biosolutions
―
Esperion
―
Aquestive Therapeutics
―
Alpha Teknova
―
Journey Medical Corp
―
Ownership Overview
30.29% Insiders
6.51% Mutual Funds
12.83% Other Institutional Investors
42.50% Public Companies and
Individual Investors